Intellia Therapeutics Inc (NASDAQ:NTLA) has a beta value of 2.13 and has seen 3.94 million shares traded in the last trading session. The company, currently valued at $956.08M, closed the last trade at $9.23 per share which meant it gained $0.03 on the day or 0.33%% during that session. The NTLA stock price is -205.31% off its 52-week high price of $28.18 and 36.08% above the 52-week low of $5.90. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.28 million shares traded. The 3-month trading volume is 4.45 million shares.
The consensus among analysts is that Intellia Therapeutics Inc (NTLA) is Buy stock at the moment, with a recommendation rating of 1.62. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 13 have rated it as a Hold, with 13 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.01.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Sporting 0.33%% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NTLA stock price touched $9.23 or saw a rise of 12.26%. Year-to-date, Intellia Therapeutics Inc shares have moved -62.78%, while the 5-day performance has seen it change 11.07%. Over the past 30 days, the shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have changed 0.33%. Short interest in the company has seen 31.56 million shares shorted with days to cover at 6.56.
Wall Street analysts have a consensus price target for the stock at $17.5, which means that the shares’ value could jump 47.26% from current levels. The projected low price target is $9.0 while the price target rests at a high of $26.0. In that case, then, we find that the current price level is -181.69% off the targeted high while a plunge would see the stock lose 2.49% from current levels.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
The company’s shares have lost -29.70% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -3.17%.
19 analysts offering their estimates for the company have set an average revenue estimate of 12.26M for the current quarter. 19 have an estimated revenue figure of 12.41M for the next ending quarter. Year-ago sales stood 6.96M and 9.11M respectively for this quarter and the next, and analysts expect sales will grow by 76.22% for the current quarter and -3.17% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -20.04% over the past 5 years. Earnings growth for 2025 is a modest 20.55% while over the next 5 years, the company’s earnings are expected to increase by 31.48%.
NTLA Dividends
Intellia Therapeutics Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Insiders own 5.01% of the company shares, while shares held by institutions stand at 97.14% with a share float percentage of 102.26%. Investors are also buoyed by the number of investors in a company, with Intellia Therapeutics Inc having a total of 415.0 institutions that hold shares in the company. The top two institutional holders are ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares worth more than $259.51 million. As of 2024-06-30, ARK INVESTMENT MANAGEMENT LLC held 11.9575% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 9.6 million shares as of 2024-06-30. The firm’s total holdings are worth over $214.79 million and represent 9.897% of shares outstanding.
